An interventional study of Ranibizumab 0.5 mg in Choroidal Neovascularization, Age-related Macular Degeneration, sponsored by Genentech, Inc.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-05-11.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 3rd largest by enrollment, is one of 4 that started in 2005, is one of 2 with no phase, and was the 5th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 853 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 5 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort enrolled patients with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). The results of the second cohort are reported separately (NCT01442064). The first cohort of this study enrolled two subsets of patients: ranibizumab experienced and ranibizumab-naive. Patients were enrolled within 14 days of completion of the 24 month treatment phase of the previous study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
Drug: Ranibizumab 0.5 mg
Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
Number of Participants With Ocular Adverse Events
Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye). Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Time frame: 36 months
Number of Participants With Non-ocular Adverse Events
Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.
Time frame: 36 months
Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24
Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.
Time frame: Month 12 and 24
Change From Baseline in Best Corrected Visual Acuity (BCVA) at a Starting Test Distance of 2 Meters
Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.
Time frame: Extension study baseline, Months 3, 6, 9, 12, 15, 18, 21 and 24
Change From Baseline in Best Corrected Visual Acuity at a Starting Test Distance of 4 Meters
Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.
Time frame: Extension study baseline, Months 12 and 24
This is an open label multicenter extension study for participants who have completed one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823). Cohort 1 includes patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).
| Milestone | RanibizumabTreated Initial Mono | RanibizumabTreated Initial + PDT | RanibizumabTreated Sham XO | Ranibizumab Treated PDT XO | Ranibizumab Untreated Group |
|---|---|---|---|---|---|
| Started | 526 | 74 | 116 | 74 | 63 |
| Received ranibizumab in extension study | 377 | 41 | 113 | 55 | 0 |
| Completed | 50 | 23 | 23 | 6 | 14 |
| Not completed | 476 | 51 | 93 | 68 | 49 |
| Withdrew: Death | 31 | 8 | 6 | 4 | 7 |
| Withdrew: Adverse event | 17 | 3 | 3 | 1 | 4 |
| Withdrew: Lost to follow-up | 8 | 1 | 2 | 1 | 4 |
| Withdrew: Physician decision | 25 | 0 | 2 | 2 | 2 |
| Withdrew: Withdrawal by subject | 94 | 11 | 19 | 7 | 14 |
| Withdrew: Subject non-compliance | 7 | 2 | 0 | 0 | 1 |
| Withdrew: Verteporfin photodynamic therapy in eye | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Subjects condition mandated intervention | 34 | 9 | 7 | 5 | 7 |
| Withdrew: Sponsor's decision | 257 | 17 | 54 | 47 | 10 |
Number of participants with ocular adverse events in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation, endophthalmitis and intraocular inflammation that occurred in the study eye (the eye that received all study drug injections) and the fellow eye (other eye). Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
| participants | Ranibizumab Treated Initial Mono | Ranibizumab Treated Initial + PDT | Ranibizumab Treated Sham XO | Ranibizumab Treated PDT XO |
|---|---|---|---|---|
| Any adverse event in study eye | 418 | 56 | 96 | 59 |
| Serious adverse events in study eye | 46 | 2 | 6 | 2 |
| Adverse events led to discontinuation, study eye | 7 | 2 | 3 | 2 |
| Endophthalmitis in study eye | 1 | 0 | 0 | 0 |
| Intraocular inflammation in study eye, total | 8 | 2 | 4 | 1 |
| Serious Intraocular inflammation in study eye | 1 | 0 | 0 | 0 |
| Any adverse event in fellow eye | 304 | 50 | 72 | 47 |
| Serious adverse events in fellow eye | 22 | 4 | 6 | 3 |
| Adverse events led to discontinuation, fellow eye | 6 | 7 | 4 | 3 |
| Endophthalmitis in fellow eye | 0 | 0 | 0 | 0 |
| Intraocular inflammation in fellow eye, total | 5 | 0 | 0 | 0 |
| Serious intraocular inflammation in fellow eye | 1 | 0 | 0 | 0 |
Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.
| participants | Ranibizumab Treated Initial Mono | Ranibizumab Treated Initial + PDT | Ranibizumab Treated Sham XO | Ranibizumab Treated PDT XO |
|---|---|---|---|---|
| Any non ocular adverse event | 427 | 61 | 92 | 58 |
| Serious non ocular adverse event | 169 | 21 | 33 | 20 |
| Non ocular adverse events led to discontinuation | 27 | 2 | 1 | 0 |
| Death | 31 | 8 | 6 | 4 |
Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 2 meters. An increase in the number of letters read indicates improvement in visual acuity.
| letters | Ranibizumab Initial Group | Ranibizumab Crossover Group | Ranibizumab Untreated Group | Total |
|---|---|---|---|---|
| Change from Baseline at Month 3 (n=284, 84, 25) | -2.9 ± 8.9 | -2.9 ± 11.0 | 0.1 ± 6.6 | -2.7 ± 9.3 |
| Change from Baseline at Month 6 (n=519, 149, 46) | -3.4 ± 8.8 | -1.6 ± 10.5 | 0.3 ± 7.0 | -2.8 ± 9.1 |
| Change from Baseline at Month 9 (n=490, 149, 38) | -4.4 ± 10.8 | -1.7 ± 11.3 | -2.2 ± 7.5 | -3.7 ± 10.8 |
| Change from Baseline at Month 12 (n=481, 142, 38) | -5.2 ± 11.1 | -2.3 ± 11.5 | -3.2 ± 8.0 | -4.5 ± 11.1 |
| Change from Baseline at Month 15 (n=447, 138, 31) | -5.6 ± 10.8 | -2.2 ± 12.4 | -3.0 ± 8.9 | -4.7 ± 11.2 |
| Change from Baseline at Month 18 (n=420, 135, 28) | -6.4 ± 11.9 | -2.0 ± 12.5 | -4.4 ± 9.5 | -5.3 ± 12.1 |
| Change from Baseline at Month 21 (n=405, 129, 28) | -7.9 ± 13.0 | -2.1 ± 13.3 | -3.5 ± 10.8 | -6.3 ± 13.2 |
| Change from Baseline at Month 24 (n=388, 127, 27) | -8.1 ± 13.0 | -2.0 ± 13.5 | -2.9 ± 8.5 | -6.4 ± 13.2 |
Change from baseline in Best corrected visual acuity (BCVA) was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a starting test distance of 4 meters. An increase in the number of letters read indicates improvement in visual acuity.
| letters | Ranibizumab Initial Group | Ranibizumab Crossover Group | Ranibizumab Untreated Group | Total |
|---|---|---|---|---|
| Change from Baseline at Month 12 (n=446,133,35) | -5.4 ± 11.8 | -1.3 ± 11.8 | -3.2 ± 7.2 | -4.4 ± 11.7 |
| Change from Baseline at Month 24 (n=352,122,25) | -7.5 ± 12.3 | -0.8 ± 13.0 | -3.1 ± 8.2 | -5.7 ± 12.7 |
Serum samples for the evaluation of antibodies to Ranibizumab were collected at Month 12 and Month 24 and were sent to a reference laboratory for analysis. If an injection of Ranibizumab was required at the visit, the samples were collected prior to the injection.
| participants | Ranibizumab Treated Initial Mono | Ranibizumab Treated Initial + PDT | Ranibizumab Treated Sham XO | Ranibizumab Treated PDT XO |
|---|---|---|---|---|
| Month 12 (n=393,55,72,50) | 10 | 0 | 1 | 0 |
| Month 24 (n=316,45,78,42) | 9 | 0 | 1 | 0 |
Collected over The summary includes adverse events that occurred from enrollment in this extension study through 36 months (+/- 7 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab Treated Initial Mono | — | 213/526 (40.5%) | 491/526 (93.3%) |
| Ranibizumab Treated Initial + PDT | — | 26/74 (35.1%) | 70/74 (94.6%) |
| Ranibizumab Treated Sham XO | — | 43/116 (37.1%) | 110/116 (94.8%) |
| Ranibizumab Treated PDT XO | — | 24/74 (32.4%) | 71/74 (95.9%) |
| Event | Ranibizumab Treated Initial Mono | Ranibizumab Treated Initial + PDT | Ranibizumab Treated Sham XO | Ranibizumab Treated PDT XO |
|---|---|---|---|---|
| MACULAR DEGENERATIONEye disorders | 21/526 | 2/74 | 5/116 | 1/74 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 8/526 | 2/74 | 1/116 | 3/74 |
| PNEUMONIAInfections and infestations | 13/526 | 1/74 | 4/116 | 0/74 |
| ATRIAL FIBRILLATIONCardiac disorders | 8/526 | 0/74 | 4/116 | 0/74 |
| CHOROIDAL NEOVASCULARISATIONEye disorders | 7/526 | 2/74 | 2/116 | 2/74 |
| LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/526 | 2/74 | 1/116 | 0/74 |
| COLON CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/526 | 0/74 | 1/116 | 2/74 |
| DEHYDRATIONMetabolism and nutrition disorders | 1/526 | 0/74 | 3/116 | 1/74 |
| SPINAL COLUMN STENOSISMusculoskeletal and connective tissue disorders | 0/526 | 0/74 | 3/116 | 1/74 |
| VISUAL ACUITY REDUCEDEye disorders | 11/526 | 1/74 | 0/116 | 0/74 |
| Event | Ranibizumab Treated Initial Mono | Ranibizumab Treated Initial + PDT | Ranibizumab Treated Sham XO | Ranibizumab Treated PDT XO |
|---|---|---|---|---|
| MACULAR DEGENERATIONEye disorders | 236/526 | 18/74 | 53/116 | 22/74 |
| RETINAL HAEMORRHAGEEye disorders | 197/526 | 21/74 | 47/116 | 31/74 |
| CONJUNCTIVAL HAEMORRHAGEEye disorders | 124/526 | 20/74 | 33/116 | 17/74 |
| CHOROIDAL NEOVASCULARISATIONEye disorders | 63/526 | 15/74 | 16/116 | 10/74 |
| CATARACTEye disorders | 61/526 | 12/74 | 8/116 | 11/74 |
| INTRAOCULAR PRESSURE INCREASEDInvestigations | 73/526 | 6/74 | 15/116 | 3/74 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 31/526 | 10/74 | 6/116 | 5/74 |
| MACULAR OEDEMAEye disorders | 70/526 | 6/74 | 15/116 | 8/74 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 31/526 | 5/74 | 5/116 | 9/74 |
| NASOPHARYNGITISInfections and infestations | 48/526 | 9/74 | 9/116 | 7/74 |
| Age, Customized(participants) | RanibizumabTreated Initial Mono | RanibizumabTreated Initial + PDT | RanibizumabTreated Sham XO | Ranibizumab Treated PDT XO | Ranibizumab Untreated Group | Total |
|---|---|---|---|---|---|---|
| 50 to < 65 | 29 | 5 | 5 | 8 | 4 | 51 |
| 65 to < 75 | 117 | 19 | 27 | 21 | 10 | 194 |
| 75 to < 85 | 277 | 42 | 61 | 35 | 29 | 444 |
| >= 85 | 103 | 8 | 23 | 10 | 20 | 164 |
| Sex: Female, Male(Participants) | RanibizumabTreated Initial Mono | RanibizumabTreated Initial + PDT | RanibizumabTreated Sham XO | Ranibizumab Treated PDT XO | Ranibizumab Untreated Group | Total |
|---|---|---|---|---|---|---|
| Female | 304 | 42 | 76 | 41 | 36 | 499 |
| Male | 222 | 32 | 40 | 33 | 27 | 354 |
No study locations are listed for this record.
The record gives a start of Apr 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Choroidal Neovascularization →